-
Tracing ASCO | Professor Yijun Shen: China-Developed Immunotherapy–ADC Combinations Take the ASCO Stage, Reshaping the Future of Genitourinary Cancer Treatment
The combination of immune checkpoint inhibitors and antibody-drug conjugates (ADCs) is rapidly expanding from the first-line treatment of advanced disease into the perioperative setting, fundamentally reshaping the treatment landscape of urothelial carcinoma (UC). As global research momentum continues to accelerate, Chinese-developed immunotherapy–ADC combinations are emerging as important contributors to this evolving field.
-
Professor Nengwang Yu’s Team at Qilu Hospital of Shandong University Reports a Novel Strategy to Enhance Bladder Cancer Chemotherapy
Recently, the team led by Professor Nengwang Yu from the Department of Urology at Qilu Hospital of Shandong University published a research article entitled “Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy” in Materials Today Bio (CAS Q1; Impact Factor: 10.2).
-
Academician Xu Zhang and Professor Jun Guo: Technological Innovation and the “Wisdom of China” Behind the Toripalimab Regimen Are Reshaping the Treatment Landscape of Urothelial Carcinoma
In recent years, rapid advances in surgical robotics and information technology have enabled remote robotic surgery to transcend geographic barriers and redefine the future of surgical care. At the same time, China’s innovative drug development efforts have achieved major international milestones. The phase III RC48-C016 study evaluating toripalimab plus disitamab vedotin (DV) as first-line treatment…
-
Professor Tianxin Lin: Advancing Clinical Care, Research, and Translation in Synergy to Build a “China Solution” for Urologic Oncology | CUDA Yanqi Lake Conference
The 2026 CUDA Yanqi Lake Urology Academic Conference was successfully held, bringing together leading urologists, clinical experts, and researchers from across China. Centered on the theme “Innovation Empowering Clinical Care, Collaboration Driving Progress,” the meeting featured in-depth discussions on key topics including advances in urologic oncology, translational innovation at the intersection of medicine and engineering,…
-
Why Does Immunotherapy Fail in Some Patients? Professor Tao Xu’s Team Uncovers a New Mechanism of Resistance in Urothelial Carcinoma
Urothelial carcinoma is one of the most common malignancies of the urinary tract, with bladder cancer representing its most prevalent subtype. In recent years, immunotherapy has offered new hope for patients with advanced disease. However, not all patients derive meaningful benefit.
-
Tumor Cells “Refuse Entry” and Actively Package for Export: Professor Zhuowei Liu’s Team Uncovers a Novel Mechanism of Resistance in Urothelial Carcinoma
On May 21, 2026, a research team led by Professor Zhuowei Liu, Dr. Zikun Ma, and Associate Research Fellow Xiaoyu Liang from Sun Yat-sen University Cancer Center published a study in Cancer Cell entitled “Endocytic Escape Drives Tumor Resistance to Antibody–Drug Conjugate Therapy.” The study systematically characterized the adaptive remodeling processes underlying resistance to antibody-drug…
-
ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape
For many years, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma, yet outcomes have remained suboptimal. As targeted therapies and immunotherapy continue to advance rapidly, there is growing demand for more effective precision treatment strategies.
-
ASCO Voices from China | Professor Xuesong Li and Professor Qi Tang: Disitamab Vedotin Plus Radiotherapy Achieves a 95% 1-Year DFS Rate, Offering an Innovative Adjuvant Strategy for UTUC in China
Upper tract urothelial carcinoma (UTUC) accounts for a substantially higher proportion of urothelial carcinoma cases in China than in Western populations. Although radical nephroureterectomy remains the standard treatment for UTUC, many patients become ineligible for cisplatin-based chemotherapy after surgery because of impaired renal function and other comorbidities. Furthermore, subgroup analyses from three major adjuvant immunotherapy…
Connecting Medical Expertise through Media